Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.

The most common reasons for discontinuing drug were ... be reduced to 25 mg once daily in patients receiving weak CYP3A4 inhibitors (such as erythromycin, saquinavir, verapamil, and fluconazole).

Harmony Biosciences Holdings, Inc. , today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, ...

Some drugs are known as nephrotoxic, which means that their effects can cause damage to the kidneys. Drugs such as certain antibiotics, the mood stabilizer lithium, and nonsteroidal anti-inflammatory ...

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

It has a plasma half-life of approximately 12 h, is cleared by both renal and hepatic routes, and undergoes limited CYP metabolism ... and selective platelet inhibitors exhibit high antithrombotic ...